4D Molecular Therapeutics (FDMT) Net Equity Issued and Repurchased (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Net Equity Issued and Repurchased of $9.7 million for Q1 2026, up 149.4% quarter-over-quarter from -$19.6 million in Q2 2024.
4D Molecular Therapeutics (FDMT) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (up 149.4% YoY), while the FY2025 annual figure was $9.6 million, down 37.1% from the prior year.
- Net Equity Issued and Repurchased improved to $9.7 million in Q1 2026 per FDMT's latest filing, from -$19.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $315.7 million in Q1 2024 and bottomed at -$19.6 million in Q2 2024.
- Historically, Net Equity Issued and Repurchased has averaged $54.2 million across 3 years, with a median of $9.6 million in 2023.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 3172.72% in 2024 and fell as far as 3172.72% in 2024.
- 4D Molecular Therapeutics' Net Equity Issued and Repurchased stood at $1000.0 in 2023, then plunged by 1963800.0% to -$19.6 million in 2024, then surged by 149.4% to $9.7 million in 2026.
- Business Quant data shows FDMT's Net Equity Issued and Repurchased at $9.7 million in Q1 2026, -$19.6 million in Q2 2024, and $315.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 21.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.84 Mn |
| Jun 30, 2026 | 21.84 Mn |
| Mar 31, 2026 | 9.70 Mn |
| Mar 31, 2026 | 9.70 Mn |
| Jun 30, 2024 | -19.64 Mn |
| Jun 30, 2024 | -19.64 Mn |
| Mar 31, 2024 | 315.72 Mn |
| Mar 31, 2024 | 315.72 Mn |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 9.49 Mn |
| Sep 30, 2023 | 9.49 Mn |
| Mar 31, 2023 | 9.65 Mn |
| Mar 31, 2023 | 9.65 Mn |
| Dec 31, 2021 | 114.30 Mn |
| Dec 31, 2021 | 114.30 Mn |
| Dec 31, 2020 | 204.70 Mn |
| Dec 31, 2020 | 204.70 Mn |
| Sep 30, 2020 | -32,000.00 |
| Sep 30, 2020 | -32,000.00 |